 |
Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val |
|---|---|
| Trade Name | |
| Orphan Indication | Chronic active hepatitis B infection in HLA-A2 positive patients |
| USA Market Approval | USA |
| USA Designation Date | 1994-03-16 00:00:00 |
| Sponsor | Cytel Corporation;3525 John Hopkins Court;San Diego, California, 92121 |
